Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: A randomized, placebo-controlled study

Medical Science Monitor

Volumn 21, Issue , 2015, Pages 163-170

  Jiang, Xue Liang ^a   Wang, Hua Hong ^b   Cui, Hui Fei ^c  

^a JINAN MILITARY GENERAL HOSPITAL   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Colitis; Inflammatory bowel diseases; Mesalamine; Ulcerativem

Indexed keywords

C REACTIVE PROTEIN; MESALAZINE; SILICATE; SILICON DIOXIDE;

ADOLESCENT; ADULT; AGED; CHEMISTRY; COLITIS, ULCERATIVE; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DEFECATION; DRUG EFFECTS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INTESTINE MUCOSA; MALE; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SEVERITY OF ILLNESS INDEX; SINGLE BLIND PROCEDURE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; DEFECATION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MESALAMINE; MIDDLE AGED; PROSPECTIVE STUDIES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SILICATES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84920953373     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.891400     Document Type: Article

References (29)

1. Kornbluth A, Sachar DB: Practice Parameters Committee of the American College of G. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol, 2010; 105: 501-23; quiz 524
2. Hanauer SB: Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis, 2006; 12(Suppl.1): S3-9
3. Mowat C, Cole A, Windsor A et al: Guidelines for the management of inflammatory bowel disease in adults. Gut, 2011; 60: 571-607
4. Feagan BG, Macdonald JK: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev, 2012; 10: CD000544
5. Moum B, Ekbom A, Vatn MH et al: Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn’s disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol, 1997; 32: 1005-12
6. Langholz E, Munkholm P, Davidsen M, Binder V: Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology, 1994; 107: 3-11
7. Takeshima F, Matsumura M, Makiyama K et al: Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis. Med Sci Monit, 2015; 21: 1314-18
8. Lee HJ, Jung ES, Lee JH et al: Long-term clinical outcomes and factors predictive of relapse after 5-aminosalicylate or sulfasalazine therapy in patients with mild-to-moderate ulcerative colitis. Hepatogastroenterology, 2012; 59: 1415-20
9. Love BL, Miller AD: Extended-release mesalamine granules for ulcerative colitis. Ann Pharmacother, 2012; 46: 1529-36
10. Faure C: Role of antidiarrhoeal drugs as adjunctive therapies for acute diarrhoea in children. Int J Pediatr, 2013; 2013: 612403
11. Khediri F, Mrad AI, Azzouz M et al: Efficacy of diosmectite (smecta) in the treatment of acute watery diarrhoea in adults: a multicentre, randomized, double-blind, placebo-controlled, parallel group study. Gastroenterol Res Pract, 2011; 2011: 783196
12. Gonzalez R, de Medina FS, Martinez-Augustin O et al: Anti-inflammatory effect of diosmectite in hapten-induced colitis in the rat. Br J Pharmacol, 2004; 141: 951-60
13. Olives JP, Rives JJ, Ghisolfi J: [Therapeutic assay of smectite in non-specific inflammations of the rectal and colonic mucosa in children. Clinical, endoscopic and histological study]. Ann Pediatr (Paris), 1987; 34: 89-92 [in French]
14. Guslandi M: Diosmectite for Ulcerative Colitis. Clin Drug Investig, 1998; 16: 411-12
15. Satsangi J, Silverberg MS, Vermeire S, Colombel JF: The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut, 2006; 55: 749-53
16. D’Haens G, Sandborn WJ, Feagan BG et al: A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology, 2007; 132: 763-86
17. Rutgeerts P, Sandborn WJ, Feagan BG et al: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med, 2005; 353: 2462-76
18. Guarino A, Lo Vecchio A, Pirozzi MR: Clinical role of diosmectite in the management of diarrhea. Expert Opin Drug Metab Toxicol, 2009; 5: 433-40
19. Su HT, Li YS, Lu SL et al: [An experimental study on the prevention of enteral bacterial translocation in scalded rats by smectite powder]. Zhonghua Shao Shang Za Zhi, 2005; 21: 89-92 [in Chinese]
20. Weese JS, Cote NM, deGannes RV: Evaluation of in vitro properties of di-trioctahedral smectite on clostridial toxins and growth. Equine Vet J, 2003; 35: 638-41
21. Hu C, Song J, Li Y et al: Diosmectite-zinc oxide composite improves intestinal barrier function, modulates expression of pro-inflammatory cytokines and tight junction protein in early weaned pigs. Br J Nutr, 2013; 110: 681-88
22. Song J, Li YL, Hu CH: Effects of copper-exchanged montmorillonite, as alternative to antibiotic, on diarrhea, intestinal permeability and proinflammatory cytokine of weanling pigs. Applied Clay Science, 2013; 77-78: 52-55
23. Turner D, Mack DR, Hyams J et al: C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis. J Crohns Colitis, 2011; 5: 423-29
24. Henriksen M, Jahnsen J, Lygren I et al: C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut, 2008; 57: 1518-23
25. Rutgeerts P, Vermeire S, Van Assche G: Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut, 2007; 56: 453-55
26. Lichtenstein GR, Rutgeerts P: Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis, 2010; 16: 338-46
27. Dupont C, Moreno JL, Barau E et al: Effect of diosmectite on intestinal permeability changes in acute diarrhea: a double-blind placebo-controlled trial. J Pediatr Gastroenterol Nutr, 1992; 14: 413-19
28. Feagan BG, Rutgeerts P, Sands BE et al: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med, 2013; 369: 699-710
29. de Souza GS, Vidigal FM, Chebli LA et al: Effect of azathioprine or mesalazine therapy on incidence of re-hospitalization in sub-occlusive ileocecal Crohn’s disease patients. Med Sci Monit, 2013; 19: 716-22